UCB finally becomes affordable
14/04/25 -"We have revised our out-year sales and EBITDA growth estimates to 3% as the previous assumption of 2% was overly conservative when compared with the 12% top-line CAGR over 2024-27. The out-year ..."
Pages
58
Language
English
Published on
14/04/25
You may also be interested by these reports :
19/04/25
Despite factoring in some margin pressure in the forecasted years, we have raised our out-year growth estimates for sales and EBITDA to 3.5% (vs. 2% ...
17/04/25
Oral, small molecule GLP-1 candidate Orforglipron shows first phase 3 results – Our take
16/04/25
Ipsen’s Q1 sales aligned with market expectations, showing healthy growth across all segments. The 2025 guidance was reaffirmed. Despite these ...
16/04/25
While Virbac’s Q1 sales slightly missed the street’s estimates, decent growth in both its segments places the firm in a position to meet its ...